Definitive Contract 75N93018C00022
Award Date
8/1/18
Potential Completion Date
1/30/20
Potential Value
$225K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Nanocomposix, Inc.
Ultimate Awardee
Not listed
PSC Category
AN91 - R&D- Medical: Other (Basic Research)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92111, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective of the contract is to develop cytomegalovirus (CMV) IgG and IgM lateral flow assays required to support a large-scale CMV vaccination trial. Nanocomposix has prior experience providing lateral flow assay devices,...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract, valued at $199,981, is for the development of nanoparticle-enabled single cell mass spectrometry technology for the detection of rare cells, under SBIR Topic 266. As a small business, Nanocomposix has been awarded previous prime...
This is a $1,000,000.00 Phase II SBIR contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract is for the rapid screening of individual cells using single cell mass spectrometry, supporting the NCI's biomedical research and development efforts. Nanocomposix has previously supported other federal agencies such as the Department of Defense...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Defense Health Agency (DHA) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The $1,000,000.00 contract is for the development of a product or technology under the SBIR program. As a Phase II award, this indicates the company previously received a Phase I contract for preliminary research and development. The contract has a cost-plus-fixed-fee pricing type and a period of...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Nanocomposix, Inc. The $200,000.00 fixed-price contract is for the development of "Surface Enhanced Fluorescence Nanotags for Ultrasensitive Multiplexed Assay Systems." As a small business manufacturer of engineered nanoparticles, Nanocomposix has previously received prime federal contracts and...
This firm fixed price purchase order contract, awarded by the Centers for Disease Control and Prevention (CDC) to Nanocomposix, Inc., is for $150,000.00 and is for research and development under the Small Business Innovation Research (SBIR) program. The contract is not set aside for a specific business type. Nanocomposix is a small business that manufactures engineered nanoparticles and has previously performed prime contracts and subcontractor work for the National Institutes of Health, Food...
This is a $999,999.99 cost-plus-fixed-fee contract awarded by the U.S. Army Medical Command (MEDCOM) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract is for a Small Business Innovation Research (SBIR) Phase II program with a target completion date of February 27, 2019. Nanocomposix has previously supported the Department of Defense and Department of Health and Human Services through prime federal contracts and subcontracts, delivering products and...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanocomposix, Inc., a manufacturer of engineered nanoparticles, to build a proof of concept lateral flow rapid diagnostic to identify the serological status of individuals with respect to cytomegalovirus (CMV). The contract, valued at $224,887.00, requires the contractor to characterize...